ArticleEuropean radiology2026
Histopathological outcomes of CT-guided high-dose-rate interstitial brachytherapy for HCC and predictive accuracy of the LI-RADS Radiation Treatment Response Algorithm v2024.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the histopathological outcomes after CT-guided high-dose-rate interstitial brachytherapy (HDR-BT) in hepatocellular carcinoma (HCC) patients and to assess the performance of the Liver Imaging Reporting and Data System (LI-RADS) Radiation treatment response algorithm (TRA). MATERIALS AND
methodsThis retrospective analysis evaluated 19 patients with 29 HCC lesions who underwent HDR-BT before liver transplantation in a single center. Lesions were evaluated for the degree of tumor necrosis on explant histopathology. The association between procedural characteristics and complete pathological necrosis on histopathology was evaluated. The medians of continuous variables were used as cutoff values. The diagnostic value of LI-RADS treatment response (LR-TR) categories was evaluated by two readers using pre-transplantation MR images.
resultsHistopathological evaluation revealed complete pathological necrosis in 19 lesions (65.5%). The remaining 10 lesions all demonstrated more than 50% tumor necrosis and showed clear evidence of apoptotic activity within the residual viable areas, as confirmed by TUNEL staining. Lesions of patients with a longer interval (> 136 days) between HDR-BT and transplantation showed significantly higher rates of complete necrosis (86.7% vs. 42.9%, p = 0.026), suggesting ongoing radiation-induced cell death and potentially therapy-induced senescence beyond the time of histological sampling. No lesion was categorized as LR-TR viable on pre-transplant MRI according to LI-RADS Radiation TRA v2024. All lesions classified as LR-TR nonviable demonstrated complete pathological necrosis on histology.
conclusionHDR-BT is associated with high rates of complete pathological necrosis in explanted livers, while LI-RADS Radiation TRA demonstrates promising performance in assessing treatment response. KEY POINTS: Question Histopathological outcomes after CT-guided high-dose-rate brachytherapy (HDR-BT) and the predictive accuracy of the LI-RADS Radiation Treatment Response Algorithm in hepatocellular carcinoma remain insufficiently defined. Findings CT-guided HDR-BT achieves high rates of complete pathological necrosis in HCC lesions, with treatment response accurately predicted by the LI-RADS Radiation TRA. Clinical relevance HDR-BT seems to be an effective bridging therapy for HCC, providing local control and high necrosis rates. LI-RADS Radiation TRA enables accurate, standardized imaging assessment to guide management and optimize timing toward transplantation.
Indexed as
Identifiers
42268301What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.